Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for May 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
FDA: Proton Pump Inhibitors Linked to Fracture Risk
WEDNESDAY, May 26 (HealthDay News) -- The U.S. Food and Drug Administration has alerted consumers and health care providers regarding the potential increased risk of hip, wrist and spine fractures associated with high doses or long-term use of proton-pump inhibitors (PPIs).
Many General Internists Leave Field by Mid-Career
FRIDAY, May 14 (HealthDay News) -- Roughly one out of six general internists are leaving internal medicine by mid-career, a substantially higher proportion compared to internal medicine subspecialists, according to survey results published April 29 in the Journal of General Internal Medicine.
New FDA Program Targets Misleading Drug Advertising
WEDNESDAY, May 12 (HealthDay News) -- The U.S. Food and Drug Administration has announced the launch of a new program to educate health care providers regarding their role in making certain that advertisements and promotions for prescription drugs are truthful and not misleading.
Copyright © 2010 ScoutNews, LLC. All rights reserved.
|Previous: May 2010 Briefing - Pulmonology||Next: May 2010 Briefing - Surgery|
Reader comments on this article are listed below. Review our comments policy.